Home > News > 13/Prognostic model development for prevalent atrial fibrillation using individual patient data from European cohorts: preliminary results from CATCH ME
Atrial Fibrillation
Read Time: 2 mins

13/Prognostic model development for prevalent atrial fibrillation using individual patient data from European cohorts: preliminary results from CATCH ME

Published Online: October 2nd 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr13
Authors: W Chua (Presenting Author) - University of Birmingham, Birmingham, UK; CL Easter - University of Birmingham, Birmingham, UK; E Guasch - Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Barcelona, Spain; AJ Sitch - University of Birmingham, Birmingham, UK; B Casadei - University of Oxford, Oxford, UK; JJ Deeks - University of Birmingham, Birmingham, UK; D Haase - Atrial Fibrillation NETwork (AFNET), Muenster, Germany; S Hatem - IHU-ICAN Institute of Cardiometabolism and Nutrition, Paris, France; K Hemming - University of Birmingham, Birmingham, UK; S Kaab - Ludwig-Maximilians University, Munich, Germany; L Mont - Hospital Clinic de Barcelona, Barcelona, Spain; U Schotten - Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; MF Sinner - Ludwig-Maximilians University, Munich, Germany; A Ziegler - Roche Diagnostics International AG, Rotkreuz, Switzerland; P Kirchhof - University of Birmingham, Birmingham, UK; L Fabritz - University of Birmingham, Birmingham, UK
Quick Links:
Article Information

Background and introduction: Atrial fibrillation (AF) can be challenging to diagnose due to asymptomatic and paroxysmal presentation. Identifying predictors associated with prevalent AF would elucidate different underlying mechanisms causing AF and potentially refine screening procedures of at-risk patients. We developed a prognostic model for prevalent AF by repurposing deeply phenotyped individual patient data from four independent European studies, and quantified the added value of cardiac blood biomarkers to the model.

Methods: Data of 120 potential predictors were harmonised in individual patient data from four independent European studies. A
three-stage Delphi expert consensus process identified relevant predictors based on clinical knowledge. Predictors which had sufficient data across all datasets were further reduced using statistical selection (backward elimination) and a logistic regression model was fitted. Odds ratios (OR) for each of the selected predictors were calculated and model performance evaluated using the C-statistic. The added predictive value of eight centrally quantified blood biomarker concentrations were calculated (Roche Diagnostics) in a subset of patients.

Results: Overall, 2,420 patients (mean [standard deviation] age = 62.7 [14.5] years, 35.6% female, 43.1% with AF) were included in the analysis. Thirty-one potential predictors identified from the Delphi process which had sufficient data across all datasets were modelled. Of these, seven were associated with increased odds of prevalent AF (age, sex, BMI, height, left atrial volume, left ventricular end systolic diameter, tricuspid valve disease of at least moderate intensity). There was an interaction between age and sex indicating an increased risk for females at older age and males at younger age (Figure 1a). The risk prediction model combining these prognostic factors performed well (C-statistic 0.79; 95%CI 0.77–0.81; see calibration plot Figure 1b). In a subset of 1,738 patients, NTproBNP and D-dimer values improved the prediction model (NTproBNP, C-statistic 0.81, 95%CI 0.79–0.83; D-dimer, C-statistic 0.82, 95%CI 0.80–0.84).

Conclusions: Our preliminary analysis identified important prognostic factors and a complex relationship between age and sex, in predicting prevalent AF, highlighting the different potential causes of AF in different patients. There is a clear need to validate these factors in external datasets and for further investigation into the molecular mechanism underlying these factors.

Article Information:

Further Resources

Share this Article
Related Content In Atrial Fibrillation
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72